Radiolabelled choline versus PSMA PET/CT in prostate cancer restaging: a meta-analysis.
PET
PSA
PSMA
choline
positron emission tomography
prostate
Journal
American journal of nuclear medicine and molecular imaging
ISSN: 2160-8407
Titre abrégé: Am J Nucl Med Mol Imaging
Pays: United States
ID NLM: 101564121
Informations de publication
Date de publication:
2019
2019
Historique:
received:
08
03
2019
accepted:
12
04
2019
entrez:
30
5
2019
pubmed:
30
5
2019
medline:
30
5
2019
Statut:
epublish
Résumé
Both radiolabelled choline and prostate specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) could be used in patients with biochemical recurrent prostate cancer (BRPCa). We aimed to perform a meta-analysis about the head-to-head comparison of detection rate (DR) between these methods in BRPCa. A comprehensive literature search of studies listed in PubMed/MEDLINE, EMBASE and Cochrane library databases through October 2018 and regarding the head-to-head comparison of DR between radiolabelled choline and PSMA PET/CT in BRPCa was carried out. Overall pooled DR was calculated on a per patient-based analysis; subgroup analyses taking into account different prostate-specific antigen (PSA) cut-off values were performed. Five studies (257 BRPCa patients) were included. The meta-analysis provided the following overall DR: 56% [95% confidence interval (95% CI): 37-75%] for radiolabelled choline PET/CT and 78% (95% CI: 70-84%) for radiolabelled PSMA PET/CT. Significant difference of DR was found only in patients with PSA ≤ 1 ng/ml [the DR of radiolabelled choline and PSMA PET/CT were 27% (95% CI: 17-39%) and 54% (95% CI: 43-65%), respectively]. Radiolabelled PSMA PET/CT proved to be clearly superior in detecting BRPCa lesions at low PSA levels (≤ 1 ng/ml) when compared to radiolabelled choline PET/CT. On the other hand, the superiority of radiolabelled PSMA PET/CT was less evident in patients with PSA > 1 ng/ml. More studies and in particular cost-effectiveness analyses comparing these imaging methods are warranted.
Types de publication
Journal Article
Langues
eng
Pagination
127-139Déclaration de conflit d'intérêts
None.
Références
Stat Med. 2002 Jun 15;21(11):1539-58
pubmed: 12111919
Stat Med. 2006 Oct 30;25(20):3443-57
pubmed: 16345038
Ann Intern Med. 2011 Oct 18;155(8):529-36
pubmed: 22007046
Clin Nucl Med. 2013 May;38(5):305-14
pubmed: 23486334
Eur J Nucl Med Mol Imaging. 2014 Jan;41(1):11-20
pubmed: 24072344
Clin Chem Lab Med. 2014 May;52(5):725-33
pubmed: 24310773
Clin Transl Oncol. 2014 Sep;16(9):770-5
pubmed: 24647843
J Nucl Med. 2015 Aug;56(8):1185-90
pubmed: 26112024
Eur J Nucl Med Mol Imaging. 2016 Jan;43(1):55-69
pubmed: 26450693
Clin Nucl Med. 2016 Jul;41(7):515-21
pubmed: 26975008
Eur J Nucl Med Mol Imaging. 2016 Jul;43(8):1410-7
pubmed: 26993315
Ann Nucl Med. 2016 Jul;30(6):385-92
pubmed: 27173771
Eur Urol. 2016 Dec;70(6):926-937
pubmed: 27363387
Nucl Med Commun. 2016 Dec;37(12):1223-1231
pubmed: 27551835
Eur J Nucl Med Mol Imaging. 2017 Jan;44(1):92-101
pubmed: 27557844
Front Oncol. 2016 Nov 09;6:225
pubmed: 27882307
Molecules. 2017 Mar 24;22(4):
pubmed: 28338640
Eur J Nucl Med Mol Imaging. 2017 Sep;44(10):1751-1776
pubmed: 28409220
Eur Urol Focus. 2018 Sep;4(5):686-693
pubmed: 28753806
Curr Radiopharm. 2018;11(1):4-13
pubmed: 29090673
Oncotarget. 2017 Nov 14;8(67):111073-111083
pubmed: 29340038
JAMA. 2018 Jan 23;319(4):388-396
pubmed: 29362800
Q J Nucl Med Mol Imaging. 2019 Mar;63(1):19-28
pubmed: 29383928
Q J Nucl Med Mol Imaging. 2019 Mar;63(1):7-18
pubmed: 29521482
Minerva Urol Nefrol. 2018 Oct;70(5):462-478
pubmed: 29664244
Eur J Hybrid Imaging. 2018;2(1):9
pubmed: 29782606
Eur J Nucl Med Mol Imaging. 2018 Nov;45(12):2035-2044
pubmed: 29922948
Clin Genitourin Cancer. 2018 Oct;16(5):385-391
pubmed: 29937067
Surg Oncol. 2018 Jun;27(2):138-145
pubmed: 29937163
World J Urol. 2018 Jul 12;:null
pubmed: 30003375
Urol Clin North Am. 2018 Aug;45(3):481-487
pubmed: 30031467
Rev Esp Med Nucl Imagen Mol. 2018 Sep - Oct;37(5):302-314
pubmed: 30139594
F1000Res. 2018 Aug 24;7:
pubmed: 30467517
Lancet Oncol. 2018 Dec;19(12):e696-e708
pubmed: 30507436
Prostate. 2019 Apr;79(5):454-461
pubmed: 30549066
Eur J Clin Invest. 2019 Mar;49(3):e13063
pubmed: 30580449
Ther Adv Urol. 2019 Jan 08;11:1756287218815793
pubmed: 30671137